Inactive Instrument

Bausch Health Companies Inc Nyse

CA91911K1021

Valeant Pharmaceuticals Intl Inc : Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference

January 07, 2012 at 01:35 am IST

MarketScreener.com By

MISSISSAUGA, Ontario, Jan. 6, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced members of its senior management team will make a presentation at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 11:30 a.m. PT. The conference will be held at the Westin St. Francis in San Francisco, CA.

A live webcast and audio archive of the presentation will be available on the company's Web site at www.valeant.com. Click on Investor Relations, and then the link to Events and Presentations. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

SOURCE Valeant Pharmaceuticals International, Inc.

Latest news about Bausch Health Companies Inc

Raymond James Initiates Bausch Health at Market Perform Rating	10/07	MT
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	21/06	MT
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	17/06	MT
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	03/06	MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	28/05	MT
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada	24/05	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	17/05	CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	15/05	MT
Bausch Health Companies Inc. Approves Directorate Appointments	15/05	CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	15/05	MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	15/05	MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	13/05	MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	03/05	MT
Bausch Health Shares Fall Following Q1 Results	02/05	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	02/05	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	02/05	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	02/05	MT
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024	02/05	CI
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
North American Morning Briefing : Stock Futures -2-	02/05	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	02/05	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01/05	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01/05	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01/05	MT

Chart Bausch Health Companies Inc

Duration

Period

More charts

Company Profile

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+63.14%	856B
NOVO NORDISK A/S	+39.55%	631B
JOHNSON & JOHNSON	-4.73%	359B
MERCK & CO., INC.	+17.42%	325B
ABBVIE INC.	+8.46%	297B
ROCHE HOLDING AG	+5.56%	234B
NOVARTIS AG	+16.44%	226B
AMGEN INC.	+14.03%	177B
PFIZER, INC.	+1.29%	165B

Other Pharmaceuticals